Skip to content

Clinical study on efficacy and safety of 30% supramolecular salicylic acid combined with 10% niacinamide in the treatment of chloasma

Clinical study on efficacy and safety of 30% supramolecular salicylic acid combined with 10% niacinamide in the treatment of chloasma - Clinical study of supramolecular salicylic acid on melasma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065346
Enrollment
Unknown
Registered
2022-11-02
Start date
2020-04-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma

Interventions

Control group:30% supramolecular salicylic acid placebo

Sponsors

Linyi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Female patients aged 25-55 years; 2. Facial pale brown to dark brown, clearly defined patches, symmetrical distribution; 3. No skin inflammation, scaling and obvious discomfort symptoms; 4. Facial discoloration in adulthood; 5. Participants are voluntary and need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. A history of 30% supramolecular salicylic acid; 2. Active herpes simplex and warts; 3. Recent history of facial surgery; 4. Oral contraceptives for nearly half a year; 5. Oral tretinoin in the past three months; 6. Working outdoors for more than two hours a day, sunburn, or insufficient light protection; 7. Salicylic acid allergy; 8. Subjects deemed unsuitable for inclusion by the researcher; 9. Pregnant and lactating women; 10. Patients with history of thrombosis, angina pectoris, myocardial infarction or cerebral ischemia before treatment; 11. Pigmentation caused by nevus fuscozygomaticus, Riehl's melanosis and pigmentotic actinic lichen planus, and melasma caused by the used hormones and cosmetics; 12. Oral administration of tranexamic acid and other whitening products in the past three months; 13. Apply antioxidant or whitening products for external use in the past three months; 14. Mental abnormalities, such as mood, skin sensitivity, etc.; 15. Photosensitive skin diseases, SLE, dermatomyositis, scleroderma, rheumatoid arthritis; 16. Within half a year after laser surgery; 17. Patients with excessive expectation of efficacy and those who did not cooperate with pre- and post-treatment photography.

Design outcomes

Primary

MeasureTime frame
mMASI score;

Secondary

MeasureTime frame
VISIA picture comparison satisfaction;Griffiths10-point evaluation method;Self-rating Anxiety Scale;Chong's self-Rating Depression Scale;L a b;TEWL;Skin moisture content;melanin;Oil and grease;The pore;The appearance of fine lines;

Countries

China

Contacts

Public ContactXiong Ying

Linyi People's Hospital

421460940@qq.com+86 15253900982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026